Literature DB >> 25051249

In vitro characterization of patches of human mesenchymal stromal cells.

Stephan Roux1, Gwellaouen Bodivit, Widy Bartis, Angélique Lebouvier, Nathalie Chevallier, Anne Fialaire-Legendre, Philippe Bierling, Helene Rouard.   

Abstract

Stem cells may represent an excellent strategy to improve the healing of skin ulcers. Today the administration mode of stem cells to skin defects remains unsatisfactory. Delivering stem cells with topical treatments represents a new strategy and answering the patients' need. Mesenchymal stromal cells (MSC) have been shown to improve wound healing of cutaneous lesions and amniotic membrane (AM) is known to represent a natural scaffold for cells. The aim of this study is to develop a tissue-engineered product combining MSC and AM for clinical use. In this work we investigated whether the stromal matrix of intact human AM could constitute a scaffold for human MSC derived from either bone marrow (BM) or adipose tissue (AT). For this purpose, clinical-grade AM, MSC, and culture medium were used. We performed experiments of short-term adherence and proliferation for 15 days after the seeding of the cells. Morphological aspects and secretion profiles of MSC onto AM were studied, respectively, by scanning electron microscopy and Luminex analysis. Results demonstrated that the stromal matrix allow the adherence in much greater amount of MSC from BM or AT compared to 2D material. Experiments of proliferation showed that both kinds of MSC could proliferate on the stromal matrix and remain viable 15 days after the seeding of the cells. The 3D analysis of MSC culture demonstrated that both types of MSC invaded the stromal matrix and grew in multiple layers while retaining their fibroblastic morphology. By studying the secretion profile of MSC onto the stromal matrix, we found that both kinds of MSC secrete important cytokines and growth factors for wound healing of cutaneous lesions, such as vascular endothelial growth factor, hepatocyte growth factor, and basic fibroblast growth factor. In conclusion, these results suggest that the stromal matrix of AM seeded with MSC represents a bioactive scaffold that should be evaluated in patients with a nonhealing cutaneous wound.

Entities:  

Mesh:

Year:  2014        PMID: 25051249      PMCID: PMC4333256          DOI: 10.1089/ten.TEA.2013.0615

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  48 in total

Review 1.  Amniotic membrane transplantation for ocular surface reconstruction.

Authors:  Merle Fernandes; Mittanamalli S Sridhar; Virender S Sangwan; Gullapalli N Rao
Journal:  Cornea       Date:  2005-08       Impact factor: 2.651

2.  The role of growth factors in the healing of chronic wounds.

Authors:  M C Robson
Journal:  Wound Repair Regen       Date:  1997 Jan-Mar       Impact factor: 3.617

3.  Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells.

Authors:  Bruno Delorme; Jochen Ringe; Nathalie Gallay; Yves Le Vern; Dominique Kerboeuf; Christian Jorgensen; Philippe Rosset; Luc Sensebé; Pierre Layrolle; Thomas Häupl; Pierre Charbord
Journal:  Blood       Date:  2007-12-17       Impact factor: 22.113

4.  Cell therapy based on adipose tissue-derived stromal cells promotes physiological and pathological wound healing.

Authors:  T G Ebrahimian; F Pouzoulet; C Squiban; V Buard; M André; B Cousin; P Gourmelon; M Benderitter; L Casteilla; R Tamarat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-02-05       Impact factor: 8.311

Review 5.  Update on tissue-engineered biological dressings.

Authors:  M Ehrenreich; Z Ruszczak
Journal:  Tissue Eng       Date:  2006-09

6.  Amniotic membrane transplantation for persistent epithelial defects with ulceration.

Authors:  S H Lee; S C Tseng
Journal:  Am J Ophthalmol       Date:  1997-03       Impact factor: 5.258

7.  Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed.

Authors:  F Cianfarani; R Tommasi; C M Failla; M T Viviano; G Annessi; M Papi; G Zambruno; T Odorisio
Journal:  Br J Dermatol       Date:  2006-01       Impact factor: 9.302

Review 8.  Preservation, sterilization and de-epithelialization of human amniotic membrane for use in ocular surface reconstruction.

Authors:  Andri K Riau; Roger W Beuerman; Laurence S Lim; Jodhbir S Mehta
Journal:  Biomaterials       Date:  2009-09-24       Impact factor: 12.479

9.  Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT).

Authors:  Philippe Bourin; Bruce A Bunnell; Louis Casteilla; Massimo Dominici; Adam J Katz; Keith L March; Heinz Redl; J Peter Rubin; Kotaro Yoshimura; Jeffrey M Gimble
Journal:  Cytotherapy       Date:  2013-04-06       Impact factor: 5.414

10.  A chemically defined carrier for the delivery of human mesenchymal stem/stromal cells to skin wounds.

Authors:  Nathan G Walker; Anita R Mistry; Louise E Smith; Paula C Eves; Grigorios Tsaknakis; Simon Forster; Suzanne M Watt; Sheila Macneil
Journal:  Tissue Eng Part C Methods       Date:  2011-11-10       Impact factor: 3.056

View more
  2 in total

Review 1.  Applications of Human Amniotic Membrane for Tissue Engineering.

Authors:  Mathilde Fénelon; Sylvain Catros; Christophe Meyer; Jean-Christophe Fricain; Laurent Obert; Frédéric Auber; Aurélien Louvrier; Florelle Gindraux
Journal:  Membranes (Basel)       Date:  2021-05-25

2.  Can supernatant from immortalized adipose tissue MSC replace cell therapy? An in vitro study in chronic wounds model.

Authors:  Honorata Kraskiewicz; Maria Paprocka; Aleksandra Bielawska-Pohl; Agnieszka Krawczenko; Kinga Panek; Judyta Kaczyńska; Agnieszka Szyposzyńska; Mateusz Psurski; Piotr Kuropka; Aleksandra Klimczak
Journal:  Stem Cell Res Ther       Date:  2020-01-21       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.